VicSIS 更新 - 服务已更改
从 2022 年 7 月起，VicSIS（维多利亚专家免疫服务网络）提供的服务发生了变化。 VicSIS 诊所的数量及其地点已经减少，成人服务现在仅在 Barwon Health、Austin Health、Monash Health 和 Peter MacCallum 癌症中心提供。由于这些变化，预约的等待时间可能会更长，因此应告知患者。
此外，VicSIS 不再资助支持儿科 COVID-19 疫苗接种。需要专家建议的 15 岁及以下儿童可以通过皇家儿童医院和莫纳什健康中心现有的专家免疫诊所进行检查。这些服务的推荐应继续通过 VicSIS eReferral 门户提交。
有关 VicSIS 的更多信息，请参阅以下链接：
ATAGI 更新了冬季剂量 COVID-19 疫苗的建议
ATAGI 扩大了推荐接受 COVID-19 冬季加强剂量的人群，现在包括：
- 任何 50 岁及以上的成年人（包括原住民和托雷斯海峡岛民）
- 16 岁及以上的老年护理或残疾护理居民
- 16 岁及以上患有严重疾病的人 免疫功能低下， 残疾或复杂的健康需求，或患有多种合并症的人，这可能会增加较差结果的可能性。
此外，任何希望降低 COVID-19 感染可能性的 30-49 岁成年人也可以接受冬季加强剂量。之前 COVID-19 感染或之前加强剂量与冬季加强剂量之间的推荐间隔为 3 个月。
ATAGI 关切地注意到，加强剂量的覆盖范围（第一剂和冬季剂）对符合条件的人群来说并不理想，并强调了疫苗接种在预防严重感染和住院方面的重要性。
要完整阅读更新后的建议，请单击以下链接：
新的免疫参考页：伤寒
伤寒和副伤寒是细菌感染，统称为肠热，由肠杆菌亚种血清型伤寒和副伤寒 A、B 和 C 引起。症状从轻微到严重不等，如果不及时治疗，可能会导致严重的并发症甚至死亡.它们可能包括长时间发烧、腹部症状或菌血症（血液中的细菌）。
我们新的参考页面概述了伤寒的症状和体征、传播途径和流行病学，以及前往伤寒流行地区旅行时可用于疾病预防的疫苗。
要阅读更多信息，请点击以下链接：
MVEC：伤寒
New immunisation reference page: Mandatory vaccine directions in Victoria
A vaccine mandate means that proof of vaccination, or an authorised medical exemption, is required in certain settings. In our new reference page, we provide information on the vaccine mandates affecting Victorians, including COVID-19 and influenza directions and “No jab, no play” and “No jab, no pay” legislations. Also included is information on the responsibility of the employee/service provider/individual and medical exemptions.
For further information, click on the link below:
MVEC: Mandatory vaccine direction in Victoria
ATAGI Statement on the Omicron variant and the timing of COVID-19 booster vaccination
In response to the emergence of the Omicron variant of COVID-19 disease and it's community transmission within Australia, the Australian Technical Advisory Group on Immunisation (ATAGI) has updated recommendations for the timing of COVID-19 vaccine booster doses.
These updated recommendations are based on strong evidence indicating that booster doses are likely to increase protection against infection with the Omicron variant, as well as reassuring international data on the safety of administering early booster doses.
These recommendations include:
- all adults (≥ 18 years) should receive a single booster dose of COVID-19 vaccine
- booster doses can be administered as early as 3 months following the completion of a primary course
- timely booster doses for pregnant women is recommended
- immunocompromised individuals who have received a 3-dose primary course should also receive a booster dose 3 months after the date of their 3rd dose
- Comirnaty (Pfizer) and Spikevax (Moderna) are the preferred brands for booster doses. Vaxzevria (AstraZeneca) can be used as a booster dose for individuals with a contraindication to receiving Comirnaty or Spikevax.
ATAGI also encourages anyone aged 12 years or older who is unvaccinated to receive COVID-19 vaccination as soon as possible.
To read the latest update in full please refer to
ATAGI Statement on the Omicron variant and the timing of COVID-19 booster vaccination
SAEFVIC Rapid report: a new reporting pathway for COVID-19 vaccine AEFI
Reporting adverse events following immunisation (AEFI) is not mandatory in Victoria, however doing so allows the rapid investigation of any potential vaccine or system problems. This helps to ensure a safe and effective immunisation program and it maintains community confidence in vaccines.
The new SAEFVIC Rapid reporting pathway has been launched for reporting any common or expected side effects following a COVID-19 vaccine. Reporting via this pathway will not result in follow up of clinical symptoms however it will contribute to data collection and assist health authorities to understand the frequency of symptoms occurring. Should the vaccinee experience significant side effects, completing the SAEFVIC Extended report is recommended.
For more information on SAEFVIC, symptoms that should be reported, and instructions on how to report, please visit our immunisation reference page below:
MVEC: Surveillance of Adverse Events Following Vaccination in the Community (SAEFVIC)
The Conversation: Let’s hold off vaccinating children and teens against COVID-19. Prioritising adults is our best shot for now
Some countries who have successfully vaccinated a high proportion of their adult population are now shifting the focus of their COVID-19 vaccine rollout towards children and adolescents.
The following article reviews various international vaccine strategies for the younger population, and explores COVID-19 vaccine safety, including expected vaccine side effects and reports of myocarditis and pericarditis in adolescents. It looks at the potential impact that vaccination of children could have on transmission, herd immunity and keeping schools open.
The World Health Organization (WHO) recognises that globally the vaccine rollout has been slow and inequitable. Low income countries have insufficient vaccine supplies to protect high-priority groups.
In Australia where rates of COVID-19 community transmission is low, it is important that efforts remain on maximising vaccine coverage for adults and those who are at highest risk of severe COVID-19 disease.
要了解更多信息，请点击以下链接：
Australia's COVID-19 vaccine coverage update- July 5 2021
The Australian Government Department of Health continue to publish information relating to the COVID-19 vaccine rollout; including data on population coverage.
Latest figures show that 71.64% of Victorians aged 70 years and over have received their first dose of COVID-19 vaccine, with 16% having completed both recommended doses.
To view these statistics and read other information relating to vaccine distribution and uptake, please refer to:
Australian Government Department of Health: Australia's COVID-19 vaccine rollout
New immunisation reference page: Myocarditis and pericarditis following mRNA COVID-19 vaccines
Myocarditis is an inflammatory disease of the heart muscle, whilst pericarditis is an inflammatory disease of the lining of the heart muscle. They are rare conditions, most commonly associated with viral infections (including SARS-CoV-2) but can also be triggered by other factors such as medications and autoimmune conditions. Globally, an increased number of cases above an expected population rate of myocarditis and pericarditis have been reported in individuals who have received mRNA COVID-19 vaccines (eg. Comirnaty™ and Moderna).
Our new reference page discusses the temporal association of myocarditis and pericarditis with mRNA COVID-19 vaccination, symptoms, investigations, as well as the implications on future COVID-19 vaccination.
要阅读更多信息，请点击以下链接：
MVEC: Myocarditis and pericarditis following mRNA COVID-19 vaccines
New immunisation reference page: Moderna COVID-19 vaccine
Following the announcement by the Australian Government that 25 million doses (as well as additional variant specific versions) of Moderna's COVID-19 vaccine, Elasomeran, had been secured for the Australian population, this vaccine was last week granted provisional determination by the TGA.
Our new reference page explores the various clinical trials involving Elasomeran, as well as details the immunogenicity, efficacy and safety data available for this vaccine.
要阅读更多信息，请点击以下链接：
MVEC: Moderna COVID-19 vaccine